EUCTR2006-004302-74-GB进行中（未招募）1 期
A Phase IV, single group study to evaluate the immunogenicity and safety in UK laboratory workers of a licensed Hib and meningococcal C conjugate combined vaccine (Menitorix) - StaMen
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Inclusion criteria will be verbally checked with potential study participants prior to enrolment. Inclusion criteria are; (1) Members of staff at manchester Health Protection Agency with occupational risk of Hib and meningococcal C disease. (2) No contradictions to vaccination as specified in the green book-Immunisation Against Infectious Disease, HMSO. (3) Written informed consent from the study participant.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •(1) Suspected or known pregnancy
研究者
相似试验
进行中（未招募）
1 期
A Phase IV, single group study to evaluate the immune response to licensed seasonal influenza vaccine and relationship of this to cytomegalovirus-associated immunosenescence in UK older adults aged 50-80 years.EUCTR2006-006563-23-GBHealth Protection Agency
进行中（未招募）
1 期
A phase IV, single group study to evaluate the magnitude of antibody response, its persistence and avidity maturation following meningococcal serogroup C conjugate booster vaccination in older children up to ten years after receipt of three doses in infancy and a booster in the second year of life - Nava boosterMeningococcal Group C DiseaseEUCTR2005-001638-34-GBHealth Protection Agency
进行中（未招募）
1 期
Evaluation of the benefits of immediate versus conventional treatment with BIC / FTC / TAF in naive patients with type 1 HIV infectioHIV infectionEUCTR2019-004871-38-ESFUNDACION JIMENEZ DIAZ HEALTH RESEARCH INSTITUTE20
进行中（未招募）
1 期
Afatinib as second-line therapy for lung cancer with EGFR mutatioMetastatic non-small cell lung cancer harbouring an EGFR mutation (Del 19 or L858R)MedDRA version: 19.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001077-14-PLBoehringer Ingelheim RCV GmbH & Co KG282
进行中（未招募）
1 期
Afatinib as second-line therapy for lung cancer with EGFR mutatioMetastatic non-small cell lung cancer harbouring an EGFR mutation (Del 19 or L858R)MedDRA version: 17.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10029521Term: Non-small cell lung cancer stage IIIBSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-001077-14-ROBoehringer Ingelheim RCV GmbH & Co KG70